Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 10,418.00p on 20-05-2025 at 16:35:12
Change 46.00p 0.44%
Buy 10,420.00p
Sell 10,414.00p
Buy / Sell AZN Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 326.00 at 10,418.00p
Day's Volume: 2,290,326
Last Close: 10,418.00p
Open: 10,440.00p
ISIN: GB0009895292
Day's Range 10,348.00p - 10,512.00p
52wk Range: 9,574.00p - 13,338.00p
Market Capitalisation: £161,499m
VWAP: 10,427.82937p
Shares in Issue: 1,550m

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Lower Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 326 10,418.00p Automatic Execution
 16:36:00 - 20-May-25
Sell* 1,000 10,418.00p Automatic Execution
 16:36:00 - 20-May-25
Sell* 474 10,418.00p Automatic Execution
 16:36:00 - 20-May-25
Sell* 526 10,418.00p Automatic Execution
 16:36:00 - 20-May-25
Sell* 74 10,418.00p Automatic Execution
 16:36:00 - 20-May-25
Sell* 204 10,418.00p SI Trade
 16:35:26 - 20-May-25
Sell* 208 10,418.00p SI Trade
 16:35:26 - 20-May-25
Sell* 209 10,418.00p SI Trade
 16:35:26 - 20-May-25
Sell* 206 10,418.00p SI Trade
 16:35:26 - 20-May-25
Sell* 203 10,418.00p SI Trade
 16:35:26 - 20-May-25
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
19th May 2025 (Mon) 10,324.00 10,372.00 10,212.00 10,372.00 2,529,943
16th May 2025 (Fri) 10,230.00 10,374.00 10,216.00 10,330.00 4,844,247
15th May 2025 (Thu) 9,946.00 10,228.00 9,932.00 10,142.00 2,520,323
14th May 2025 (Wed) 10,164.00 10,252.00 10,010.00 10,022.00 3,887,993
13th May 2025 (Tue) 10,354.00 10,394.00 10,164.00 10,180.00 1,526,868
12th May 2025 (Mon) 9,743.00 10,320.00 9,651.00 10,272.00 3,037,101
9th May 2025 (Fri) 10,140.00 10,328.00 10,132.00 10,240.00 2,846,036
8th May 2025 (Thu) 10,406.00 10,428.00 10,100.00 10,134.00 2,287,586
7th May 2025 (Wed) 10,478.00 10,554.00 10,392.00 10,504.00 3,690,675
6th May 2025 (Tue) 10,890.00 10,902.00 10,674.00 10,700.00 2,983,792
5th May 2025 (Mon) 10,885.1479 10,885.1479 10,885.1479 10,885.1479 6,765
2nd May 2025 (Fri) 10,656.00 10,790.00 10,600.00 10,754.00 2,368,624
1st May 2025 (Thu) 10,766.00 10,778.00 10,444.00 10,608.00 1,222,578
30th Apr 2025 (Wed) 10,820.00 10,892.00 10,676.00 10,728.00 3,299,474
29th Apr 2025 (Tue) 10,050.00 10,620.00 9,978.00 10,618.00 2,494,155
28th Apr 2025 (Mon) 10,416.00 10,582.00 10,410.00 10,526.00 3,425,539
25th Apr 2025 (Fri) 10,470.00 10,502.00 10,332.00 10,400.00 2,801,443
24th Apr 2025 (Thu) 10,356.00 10,450.00 10,274.00 10,444.00 4,024,694
23rd Apr 2025 (Wed) 10,262.00 10,486.00 10,226.00 10,362.00 4,199,089
22nd Apr 2025 (Tue) 10,122.00 10,158.00 9,845.00 10,140.00 2,355,326
21st Apr 2025 (Mon) 10,124.00 10,124.00 10,124.00 10,124.00 0
See more Astrazeneca price history

Astrazeneca (AZN) Regulatory News

Date Source Headline
9th May 2025 7:00 am RNS Imfinzi improved DFS in early bladder cancer
7th May 2025 7:30 am RNS Enhertu improved pCR in early-stage breast cancer
6th May 2025 7:00 am RNS Calquence combination approved in EU for 1L MCL
2nd May 2025 7:00 am RNS Breztri met primary endpoints in Ph3 asthma trials
1st May 2025 4:00 pm RNS Director/PDMR Shareholding
1st May 2025 3:00 pm RNS Total Voting Rights
29th Apr 2025 7:10 am RNS Fixed-duration Calquence recommended in EU for CLL
29th Apr 2025 7:05 am RNS Update on CAPItello-280 Phase III trial
29th Apr 2025 7:00 am RNS 1st Quarter Results
22nd Apr 2025 7:00 am RNS Enhertu combination improved PFS in 1L HER2+ mBC
See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

AstraZeneca completes EsoBiotec acquisition for up to USD1 billion

20th May 2025 08:55

(Alliance News) - AstraZeneca PLC on Tuesday said it has completed its acquisition of Belgian biotechnology firm EsoBiotec SA, bolstering its cell therapy capabilities with a platform that could significantly accelerate cancer treatment delivery. Read More

IN BRIEF: AstraZeneca trial shows Airsupra effective against asthma

19th May 2025 19:54

AstraZeneca PLC - Cambridge-based pharmaceutical and biotechnology company - Phase 3b Batura trial shows statistically significant and clinically meaningful improvements in mild asthma in patients treated with Airsupra (albuterol and budesonide) than albuterol alone. Compared to placebo, Airsupra significantly reduces the risk of a severe symptom exacerbation by 47%. Patients treated with airsupra have 63% lower exposure to total systemic corticosteroids over the treatment period compared with albuterol-alone, reducing risks from cumulative exposure to SCS which include type 2 diabetes, depression and anxiety, renal impairment, cataracts, cardiovascular disease, pneumonia and fractures. Read More

LONDON MARKET CLOSE: Stocks rise amid trade de-escalation boost

16th May 2025 17:01

(Alliance News) - The FTSE 100 pushed higher on Friday, ending the week on a strong note, and now at the level it roughly stood at prior to US President Donald Trump's 'liberation day' tariff melee. Read More

LONDON MARKET MIDDAY: FTSE 100 outperforms as Europe underwhelms

15th May 2025 12:13

(Alliance News) - London's FTSE 100 outperformed European peers, though a share price fall for oil majors and a host of other shares that went ex-dividend kept a lid on the blue-chip index's progress. Read More

AstraZeneca gets UK approval for Trixeo with eco-friendly propellant

12th May 2025 09:09

(Alliance News) - AstraZeneca PLC on Monday announced that its medicine Trixeo Aerosphere has been approved by the UK Medicines & Healthcare Products Regulatory Agency with "an innovative, next-generation propellant with near-zero global warming potential". Read More

See more Astrazeneca news
FTSE 100 Latest
Value8,781.12
Change81.81

Login to your account

Forgot Password?

Not Registered